Rebel Congress MLA Umesh Jadhav denies reports about he joining BJP

News Network
January 24, 2019

Chincholi, Jan 24: The Rebel Congress MLA Dr Umesh Jadhav, who defied the party’s direction to attend the Congress Legislative Party (CLP) meeting on Friday last, has denied the media reports that he plans to join the Bharatiya Janata Party (BJP).

Speaking to newsmen here on Thursday, at his native village Pedasur, Jadhav, said that “I am still in Congress and have not quit the party”.

Strongly denying the media reports, that he has plans to join the Saffron party, he said that “I will consult the people of my constituency before taking any decision”.

Comments

Nayaz
 - 
Thursday, 24 Jan 2019

Consult the people of his constituency....is he going to have another round of elections for his constituency....weired........

kumar
 - 
Thursday, 24 Jan 2019

This shows how desparate and feared bjp is .   They are doing illegal and unconstitutional things now a days.  They are spreading rumour that many congress and ohter party MLA and MPs are joining bjp.   This is like day time robbery headed by chowkidar.   bjp is sure that they will be kicked out by public soon and hence they are trying to mislead common indian by giving wrong informatin.   they are trying to divert public attention from main issues of non employment + emptying of Govt money + death of farmer and poors due to powerty + shame in foreign countries etc etc.   

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
coastaldigest.com news network
August 1,2020

Bengaluru, Jul 31: A total of 5,483 new COVID-19 cases and 84 deaths were reported in Karnataka in the last 24 hours, the state's health department informed on Friday.

Karnataka now has a total of 1,24,115 coronavirus cases, including 72,005 active cases and 49,788 discharges.
So far, 2,134 deaths have been reported from the state.

Meanwhile, India reported the highest single-day spike of 55,079 COVID-19 cases in the last 24 hours, crossing the 16-lakh mark, the Ministry of Health and Family Welfare informed on Friday.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
coastaldigest.com web desk
July 1,2020

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 12,2020

Bengaluru, Apr 12: Former chief minister H D Kumaraswamy on Sunday appealed to the Central government to announce the rent rebate scheme for the benefit of tenants in the wake of economic activities coming to a grinding halt due to COVID-19 related lockdown.

In a series of tweets, Kumaraswamy said people are facing difficulty in paying rent as usual and hence the rent rebate scheme should be initiated.

"Many countries have already announced rent rebate scheme for tenants during COVID19 emergency. It is surprising that Indian Govt has not announced any such relief even to residential tenants. I urge the PM to immediately come to the rescue of everyone living in rented housing," Kumaraswamy tweeted.

He said a considerable workforce and students in metropolitan cities live in hostels and rented houses.

As all economic activity has come to a grinding halt, it is very difficult for them to pay the rent as usual.

The Prime Minister must announce rent rebate scheme, he added.

Highlighting the plight of the tenants, Kumaraswamy said, "If the landlords insist on rent, the tenants cannot even go searching for new accommodation due to the emergency. Hence the government intervention is essential. The PM must announce a comprehensive national rent rebate scheme for COVID-19 emergency."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.